Redx Pharma plc Notice of AGM (2225O)
February 05 2021 - 12:24PM
UK Regulatory
TIDMREDX
RNS Number : 2225O
Redx Pharma plc
05 February 2021
REDX PHARMA PLC
("Redx" or "the Company" or "Redx Pharma")
Notice of Annual General Meeting and guidance for
shareholders
Alderley Park, 5 February 2021 Redx Pharma (AIM:REDX), the drug
discovery and development Company focused on oncology and fibrosis,
today announces that its Annual General Meeting will be held at
11am on 2 March 2021 at Block 33, Mereside, Alderley Park,
Macclesfield SK10 4TG.
Following the announcement of preliminary results for the
financial year ended 30 September 2020 on 27 January, the Company
announces that the Annual Report and Accounts and notice of Annual
General Meeting have now been posted to shareholders. The Annual
Report and Accounts is also available to view on Redx's website at
www.redxpharma.com .
In light of the Stay-at-Home Measures which prohibit all
non-essential travel and larger public gatherings and to ensure the
safety of the limited number of people whose attendance at the
meeting is essential, shareholders will not be allowed into the
Annual General Meeting.
At previous Annual General Meetings, once the formal business of
the Meeting has been completed, management have taken the
opportunity to provide a business update presentation to those
shareholders who attend the meeting in person. This year, given
measures associated with the COVID-19 pandemic, such a presentation
will not be provided and the Meeting shall focus entirely upon
conducting the formal business of the Meeting. However, the Company
values engagement with its shareholders and, accordingly,
shareholders may submit questions related to the business of the
AGM to the directors in advance of the Meeting. Questions should be
submitted by 5:30 p.m. on 25 February 2021 and addressed to Andrew
Booth, Company Secretary, by email at a.booth@redxpharma.com.
Following the AGM, the Board will respond to any questions
submitted by shareholders in advance of the meeting and the answers
will be posted on the investor FAQs section of the Company
website.
Shareholders are strongly encouraged to vote by proxy,
appointing the Chairman of the meeting, using the card distributed
with the notice of meeting, to ensure their vote counts. The proxy
is also available in the investor resources section of the
Company's website: www.redxpharma.com
Completed proxies should be returned to:
Equiniti
Aspect House
Spencer Road
Lancing
BN99 6DA
and must be received by 11am on 26 February 2021 to be
valid.
The COVID-19 situation continues to evolve, and further
announcements regarding the Annual General Meeting may be required
in due course. The Company will seek to ensure that shareholders
remain fully informed at all times.
For further information, please contact:
Redx Pharma Plc T: +44 1625 469
918
Iain Ross, Chairman
Lisa Anson, Chief Executive Officer
James Mead, Chief Financial Officer
SPARK Advisory Partners (Nominated Adviser) T: +44 203 368
3550
Matt Davis/Adam Dawes
WG Partners LLP (Broker) T: +44 20 3705
9330
Claes Spång/Chris Lee/David Wilson
FTI Consulting T: +44 20 3727
1000
Simon Conway/Ciara Martin
About Redx Pharma Plc
Redx Pharma (AIM:REDX) is focused on the discovery and
development of novel targeted medicines for the treatment of cancer
and fibrotic disease, aiming to progress them to clinical Proof of
Concept. Redx's lead oncology asset, RXC004, is currently in a
Phase 1 study in patients with advanced malignancies with top line
data expected in H1 2021 and the Company's selective ROCK2
inhibitor, RXC007, is expected to enter a Phase 1 clinical study in
H1 2021.
The Company's core capability of converting medicinal chemistry
insights into differentiated and commercially attractive small
molecule drug candidates against clinically validated targets has
been recognized by others. Over the last three years the company
has completed four major preclinical stage deals with AstraZeneca,
Jazz Pharmaceuticals and Loxo Oncology (now Eli Lilly).
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOAUPUPPPUPGGMA
(END) Dow Jones Newswires
February 05, 2021 12:24 ET (17:24 GMT)
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Sep 2023 to Sep 2024